A PILOT STUDY OF STANDARD-DOSE RITUXIMAB, IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE (RICE) PLUS BORTEZOMIB (VELCADE) IN A DOSE-ESCALATING FASHION FOR PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN'S LYMPHOMA WHO ARE CANDIDATES FOR AUTOLOGOUS STEM CELL TRANSPLANT: